Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image
Active
Mainboard

Sudeep Pharma Ltd

Sudeep Pharma Ltd IPO Details

Listing Date

28 Nov 2025

Bid Price

₹563 - ₹593

Lot Size

25 Shares

Minimum Investment

₹14,825 / Lot

Issue Size

₹895 Crores

Schedule

    Here are the important dates you need to know in order to participate in this IPO

tick

Bidding starts

21st Nov

tick

Bidding ends

25th Nov

tick

Allotment of shares

26th Nov

tick

Initiation of refund

27th Nov

tick

Credit of shares to Demat account

27th Nov

tick

Listing date

28th Nov

About Sudeep Pharma Ltd IPO

Sudeep Pharma Ltd, founded in 1989, is seeking to raise about ₹95 crore through a fresh issue in its IPO, alongside a promoter-led offer-for-sale of roughly 1,00,76,492 shares. The company intends to deploy approximately ₹75.81 crore of the fresh proceeds toward capital expenditure, particularly for machinery procurement at its Nandesari facility. At the same time, the rest is earmarked for general corporate purposes.
 

On the business side, Sudeep Pharma is a manufacturer of excipients and speciality mineral-based ingredients for the pharmaceutical, food, and nutrition sectors. It operates three manufacturing facilities in Vadodara, Gujarat, with a combined capacity of 65,579 metric tonnes as of 31 December 2024. The company has a global presence, supplying customers in over 100 countries. Its financials for the nine months ended 31 December 2024 show a revenue of ₹344.45 crore and a profit after tax of ₹94.54 crore.

Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 89.37% 76.15%
Public Group 10.63% 23.85%

Sudeep Pharma Ltd IPO Reservation

QIB Shares Offered 30,18,550 (20%)
NII (HNI) Shares Offered 22,63,913 (15%)
Retail Shares Offered 52,82,462 (35%)
Anchor Investor Shares Offered 45,27,825 (30%)
Total Shares Offered 1,50,92,750
Total Shares With Anchor Investor 1,50,92,750

Sudeep Pharma Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 25 ₹14,825
Retail (Max) 13 325 ₹1,92,725
S HNI (Min) 14 350 ₹2,07,550
S HNI (Max) 67 1,675 ₹9,93,275
B HNI (MIN) 68 1,700 ₹10,08,100

Sudeep Pharma Ltd IPO Anchor Portion Size

Bid Date November 20, 2025
Shares Offered 45,27,823
Anchor Investment Details 268.4999039

Sudeep Pharma Ltd IPO registrar

MUFG Intime India Pvt Ltd
Phone Number +91 81 0811 4949
Email Id sudeeppharma.ipo@in.mpms.mufg.com
Website https://in.mpms.mufg.com

Sudeep Pharma Ltd IPO Lead Manager

1. ICICI Securities Limited

2. IIFL Capital Services Limited

Sudeep Pharma Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2022
Net Worth ₹493.09 cr ₹356 cr ₹163.34 cr
Reserves and Surplus ₹481.11 cr ₹354.59 cr ₹161.93 cr
Total Borrowing ₹135.25 cr ₹75.03 cr ₹83.69 cr

Sudeep Pharma Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid Subscription (Times)
Qualified Institutional Buyers (QIBs) 30,18,550 64,31,88,450 213.08
Non Institutional Investors (NIIs) 22,63,913 26,42,40,450 116.72
Retail Individual Investors (RIIs) 52,82,463 8,26,71,250 15.65
Total 1,05,64,926 99,01,00,150 93.72

Strength of Sudeep Pharma Ltd

  • Market leadership with a diversified product portfolio in a high barrier industry.
  • Distinguished global customer base with long-standing relationships with key customers.
  • Well-equipped and regulatory compliant Manufacturing Facilities.
  • Strong research and development capabilities.
  • Experienced Promoters and senior management team.

Risks Involved

  • The company generates a significant portion of its revenues from a limited number of customers and the loss of such customers or a decline in demand from such customers could adversely affect the company's business, results of operations, financial condition, and cash flows.
  • The company generated 66.43%, 65.84%, 67.64% and 77.01% of its revenue from operations from the company's pharmaceutical, food and nutrition segment, in the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. Any adverse developments affecting this segment may adversely affect its business, results of operations, financial condition, and cash flows.
  • The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers and any manufacturing or quality control problems may subject us to regulatory action, damage its eputation and have an adverse effect on its business and results of operations.
  • Three of the company's four Manufacturing Facilities and one of its two R&D facilities are concentrated in a single region and any adverse developments affecting this region could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
  • Any disruption, slowdown or shutdown in the company's manufacturing or R&D operations could adversely affect its business, results of operations, financial condition and cash flows.
  • The company generates a substantial portion of its revenue from operations from the company's export sales (58.68%, 59.27%, 64.43% and 68.45% of its revenue from operations for the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively) and any adverse developments in such regions, including the imposition of tariffs or other anti-sourcing legislation, could adversely affect the company's business, results of operations, financial condition and cash flows.
  • If the company is unable to introduce new products in a timely manner or if the products the company commercialize do not perform as expected, the company's business, results of operations, financial condition and cash flows may be adversely affected.
  • The company has recently undertaken the NSS Acquisition and may undertake similar acquisitions, investments, joint ventures or other strategic alliances in the future, which if unsuccessful, may adversely affect its business, results of operations and financial condition.
  • Any delay, interruption or reduction in the supply of raw materials and equipment to manufacture the company's products may adversely affect its business, results of operations, financial condition and cash flows.
  • The company's past performance may not be indicative of its future growth. The company may not be successful in implementing and managing its expansion and growth strategy effectively. Further, the company intend to diversify into different businesses beyond the pharmaceutical sphere, and failures to successfully implement such business ventures can negatively impact the company's results of operations and financial condition.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Sudeep Pharma IPO

  • The Indian pharmaceutical-ingredients space is supported by growing demand for excipients and specialty minerals, especially calcium-based products.

  • Sudeep Pharma operates in both the pharmaceutical and nutrition verticals, tapping into cross-industry tailwinds.

  • The company has an established global footprint, supplying to over 100 countries, which aligns with rising export trends in pharma ingredients.

  • Its production capacity is relatively large (65,579 metric tonnes across three plants), positioning it to scale with demand.

  • Acquisition of a European premix business (Nutrition Supplies Services) could help broaden its reach into infant and clinical nutrition — markets projected to grow.

  • Quality certifications (e.g., European suitability for its calcium products) could provide regulatory edge in international markets.

  • The broader Indian pharma industry is projected to grow, driven by domestic demand, innovation, and increasing global relevance.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sudeep Pharma IPO.

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Victory Electric Vehicles International Limited IPO
Bidding Period
7th Jan 2026 - 1st Jan 2026
Price Range
₹41.0 - 41.0
IPO Size
₹34,56,00,000
Yajur Fibres Limited IPO
Bidding Period
7th Jan 2026 - 1st Jan 2026
Price Range
₹168.0 - 174.0
IPO Size
₹1,20,41,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amagi Media Labs Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amir Chand Jagadish Kumar Exports Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
APPL Containers Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
MODERN DIAGNOSTIC AND RESEARCH CENTRE LIMITED IPO
Bidding Period
31st Dec 2025 - 1st Jan 2026
Price Range
₹85.0 - 90.0
IPO Size
₹37,00,00,000
E TO E TRANSPORTATION INFRASTRUCTURE LIMITED IPO
Bidding Period
26th Dec 2025 - 12th Dec 2025
Price Range
₹164.0 - 174.0
IPO Size
₹84,22,00,000
DHARA RAIL PROJECTS LIMITED IPO
Bidding Period
23rd Dec 2025 - 12th Dec 2025
Price Range
₹120.0 - 126.0
IPO Size
₹50,20,00,000
ADMACH SYSTEMS LIMITED IPO
Bidding Period
23rd Dec 2025 - 12th Dec 2025
Price Range
₹227.0 - 239.0
IPO Size
₹42,60,00,000
APOLLO TECHNO INDUSTRIES LIMITED IPO
Bidding Period
23rd Dec 2025 - 12th Dec 2025
Price Range
₹123.0 - 130.0
IPO Size
₹47,96,00,000
BAIKAKAJI POLYMERS LIMITED IPO
Bidding Period
23rd Dec 2025 - 12th Dec 2025
Price Range
₹177.0 - 186.0
IPO Size
₹1,05,17,00,000
NANTA TECH LIMITED IPO
Bidding Period
23rd Dec 2025 - 12th Dec 2025
Price Range
₹209.0 - 220.0
IPO Size
₹31,81,00,000
DACHEPALLI PUBLISHERS LIMITED IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹100.0 - 102.0
IPO Size
₹40,39,00,000
EPW INDIA LIMITED IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹95.0 - 97.0
IPO Size
₹31,81,00,000
GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹108.0 - 114.0
IPO Size
₹2,50,80,00,000
SHYAM DHANI INDUSTRIES LIMITED IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹65.0 - 70.0
IPO Size
₹38,49,00,000
SUNDREX OIL COMPANY LIMITED IPO
Bidding Period
22nd Dec 2025 - 12th Dec 2025
Price Range
₹81.0 - 86.0
IPO Size
₹32,25,00,000
PHYTOCHEM REMEDIES INDIA LIMITED IPO
Bidding Period
18th Dec 2025 - 12th Dec 2025
Price Range
₹98.0 - 98.0
IPO Size
₹38,22,00,000
MARC TECHNOCRATS LIMITED IPO
Bidding Period
17th Dec 2025 - 12th Dec 2025
Price Range
₹88.0 - 93.0
IPO Size
₹42,59,00,000
KSH INTERNATIONAL LIMITED IPO
Bidding Period
16th Dec 2025 - 12th Dec 2025
Price Range
₹365.0 - 384.0
IPO Size
₹7,10,00,00,000
NEPTUNE LOGITEK LIMITED IPO
Bidding Period
15th Dec 2025 - 12th Dec 2025
Price Range
₹126.0 - 126.0
IPO Size
₹46,62,00,000
ICICI PRUDENTIAL ASSET MANAGEMENT CO LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹2061.0 - 2165.0
IPO Size
₹1,06,02,65,00,000
EXIM ROUTES LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹83.0 - 88.0
IPO Size
₹43,73,00,000
ASHWINI CONTAINER MOVERS LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹135.0 - 142.0
IPO Size
₹71,00,00,000
STANBIK AGRO LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹30.0 - 30.0
IPO Size
₹12,28,00,000
  • All
  • MainBoard
  • SME
E TO E TRANSPORTATION INFRASTRUCTURE LIMITED IPO
Issue Prize
174.00
Listing Day Close
327.80(88.51%)
DHARA RAIL PROJECTS LIMITED IPO
Issue Prize
126.00
Listing Day Close
157.50(25.40%)
ADMACH SYSTEMS LIMITED IPO
Issue Prize
239.00
Listing Day Close
200.75(-15.90%)
APOLLO TECHNO INDUSTRIES LIMITED IPO
Issue Prize
130.00
Listing Day Close
151.95(16.92%)
BAIKAKAJI POLYMERS LIMITED IPO
Issue Prize
186.00
Listing Day Close
188.20(1.08%)
NANTA TECH LIMITED IPO
Issue Prize
220.00
Listing Day Close
245.70(11.82%)
DACHEPALLI PUBLISHERS LIMITED IPO
Issue Prize
102.00
Listing Day Close
79.15(-22.55%)
EPW INDIA LIMITED IPO
Issue Prize
97.00
Listing Day Close
116.55(20.62%)
GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED IPO
Issue Prize
114.00
Listing Day Close
104.65(-7.89%)
SHYAM DHANI INDUSTRIES LIMITED IPO
Issue Prize
70.00
Listing Day Close
139.65(100.00%)
SUNDREX OIL COMPANY LIMITED IPO
Issue Prize
86.00
Listing Day Close
65.40(-24.42%)
MARC TECHNOCRATS LIMITED IPO
Issue Prize
93.00
Listing Day Close
70.70(-23.66%)
KSH INTERNATIONAL LIMITED IPO
Issue Prize
384.00
Listing Day Close
354.55(-7.55%)
NEPTUNE LOGITEK LIMITED IPO
Issue Prize
126.00
Listing Day Close
95.80(-23.81%)
ICICI PRUDENTIAL ASSET MANAGEMENT CO LIMITED IPO
Issue Prize
2165.00
Listing Day Close
2586.70(19.49%)
EXIM ROUTES LIMITED IPO
Issue Prize
88.00
Listing Day Close
115.50(31.82%)
ASHWINI CONTAINER MOVERS LIMITED IPO
Issue Prize
142.00
Listing Day Close
140.10(-1.41%)
STANBIK AGRO LIMITED IPO
Issue Prize
30.00
Listing Day Close
33.33(10.00%)
HRS ALUGLAZE LIMITED IPO
Issue Prize
96.00
Listing Day Close
132.30(37.50%)
PAJSON AGRO INDIA LIMITED IPO
Issue Prize
118.00
Listing Day Close
130.20(10.17%)

Frequently Asked Questions

What is Sudeep Pharma Ltd IPO?

Answer Field

Sudeep Pharma Ltd IPO is a Mainboard IPO of 1,50,92,750 equity shares of a face value of ₹1 aggregating up to ₹895 Crores. The issue is priced at ₹563 to ₹593 per share. The minimum order quantity is 25 Shares. The IPO opens on November 21, 2025, and closes on November 25, 2025. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Sudeep Pharma Ltd IPO will open?

Answer Field

The Sudeep Pharma Ltd IPO opens on November 21, 2025 and closes on November 25, 2025.

What is the lot size of Sudeep Pharma Ltd?

Answer Field

Sudeep Pharma Ltd lot size is 25 shares, and the minimum amount required is ₹14,825.

How to apply for Sudeep Pharma Ltd IPO?

Answer Field

You can apply in Sudeep Pharma Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Sudeep Pharma Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Sudeep Pharma Ltd IPO will be done on November 26, 2025, and the allotted shares will be credited to your demat account by November 27, 2025.

When is Sudeep Pharma Ltd IPO listing date?

Answer Field

The Sudeep Pharma Ltd listing date is November 28, 2025.

Who is the registrar of Sudeep Pharma Ltd IPO?

Answer Field

The registrar of Sudeep Pharma Ltd IPO is MUFG Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

ICICI Securities Limited,IIFL Capital Services Limited will be the book-running lead manager of this IPO.

What is the fresh issue of Sudeep Pharma Ltd IPO?

Answer Field

The fresh issue size is ₹95 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Sudeep Pharma Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 25 shares and ₹14,825 amount.

How can I approve the UPI mandate request for Sudeep Pharma Ltd IPO?

Answer Field

To apply for Sudeep Pharma Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Sudeep Pharma Ltd?

Answer Field

The price of each Sudeep Pharma Ltd share will be ranging in between ₹563 to ₹593 per share.

What is the cut-off time for the UPI mandate for Sudeep Pharma Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, November 25, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|